Drugs That Distort the Watt Test and VO2 Max: What Skews Your Results

What the Watt Test and VO2 Max Actually Measure

The Watt test and VO2 max assessment quantify two related but distinct endpoints of cardiorespiratory fitness (CRF). VO2 max represents the maximum rate at which the body can consume oxygen during progressive exercise, expressed as mL/kg/min. The Watt test records the highest sustained power output (in watts) a person can produce on a cycle ergometer before volitional exhaustion.

Both tests follow graded protocols. The subject pedals or runs at progressively increasing intensity while expired gases are analyzed breath-by-breath. VO2 max is reached when oxygen consumption plateaus despite rising workload 1. Peak watt output from the same session is the complementary metric. The American Heart Association's 2016 scientific statement classified CRF as a clinical vital sign, noting that each 1-MET increase in fitness corresponds to roughly a 13% reduction in all-cause mortality 2. Because these tests track longevity risk and training response, any pharmacologic distortion compromises clinical interpretation.

A single test result means little in isolation. Serial measurements over months or years are where the prognostic value lives. That makes consistency of testing conditions, including medication status, non-negotiable.

Normal Ranges and What They Mean Clinically

For men aged 30 to 39, a VO2 max between 35 and 45 mL/kg/min is typical. For women in the same bracket, 27 to 37 mL/kg/min. Elite endurance athletes exceed 70 mL/kg/min; sedentary adults over 60 may fall below 20 mL/kg/min 3.

Dr. Peter Attia has called VO2 max "perhaps the single most powerful marker of longevity," referencing data from a 2022 JAMA Network Open study (N=750,302) that found individuals in the lowest CRF quintile had a hazard ratio of 4.09 for all-cause mortality compared to those in the highest quintile 4. Watt-test output follows a parallel curve: peak power declines roughly 1 to 2% per year after age 30 in untrained populations.

A VO2 max below 17.5 mL/kg/min in older adults predicts functional dependence and elevated cardiovascular event rates 5. Clinicians increasingly use CRF testing to stratify patients before prescribing exercise programs, adjusting metabolic therapies, or evaluating perioperative risk. If a medication is artificially pulling the number up or down, risk stratification fails.

Drugs That Artificially Lower VO2 Max and Watt Output

Beta-Blockers

This is the most clinically significant drug class for test distortion. Beta-adrenergic blockers (metoprolol, atenolol, propranolol, carvedilol) cap maximal heart rate, directly limiting cardiac output at peak effort. A meta-analysis of 15 studies found that non-selective beta-blockers reduced VO2 max by a mean of 11.6%, while cardioselective agents reduced it by 8.2% 6. The blunting effect is dose-dependent.

Patients on beta-blockers will also show suppressed peak watt values. The test is not "wrong" per se. It reflects true physiological capacity under the drug. But comparing a beta-blocked test to a prior unmedicated baseline will falsely suggest CRF decline.

Calcium Channel Blockers

Non-dihydropyridine agents (verapamil, diltiazem) reduce heart rate and myocardial contractility. The VO2 max reduction is smaller than beta-blockers, typically 3 to 7%, but clinically relevant for longitudinal tracking 7.

Sedatives and Centrally Acting Agents

Benzodiazepines, gabapentinoids, and centrally acting alpha-2 agonists (clonidine) impair motor recruitment and reduce central drive. The result is premature test termination rather than a true physiologic plateau. Peak watts drop. VO2 max appears lower because the patient stopped before reaching their actual ceiling.

Diuretics

Loop diuretics (furosemide) and thiazides reduce plasma volume. An acute 3% reduction in blood volume can decrease stroke volume enough to lower VO2 max by 3 to 5% 8. Patients tested in a volume-depleted state from aggressive diuretic dosing will underperform.

Drugs That Artificially Raise VO2 Max and Watt Output

Erythropoietin and Blood Doping

Recombinant human EPO (rHuEPO) increases hemoglobin concentration, expanding oxygen delivery. A landmark study by Lundby et al. demonstrated that four weeks of rHuEPO administration raised VO2 max by 7% (from 51.1 to 54.7 mL/kg/min) in trained cyclists, with hemoglobin increasing from 14.6 to 15.9 g/dL 9. Autologous blood transfusion produces comparable effects: one additional unit of packed red blood cells can raise VO2 max by roughly 5 to 7%.

Testosterone and Anabolic Agents

Testosterone replacement therapy (TRT) increases erythropoiesis. The Testosterone Trials (TTrials) showed that one year of transdermal testosterone raised hemoglobin by a mean of 1.0 g/dL in men aged 65 and older 10. Each 1 g/dL hemoglobin increase adds roughly 4% to oxygen-carrying capacity. TRT also increases lean mass and may improve peripheral oxygen extraction, both of which inflate Watt-test output independently of true fitness gains.

Supraphysiologic doses of nandrolone, oxandrolone, or other anabolic-androgenic steroids amplify these effects further. A patient starting TRT who repeats CRF testing three months later may show improved VO2 max that reflects hematologic changes, not training adaptation.

Stimulants

Amphetamine-based medications (Adderall, Vyvanse, methamphetamine), methylphenidate, and modafinil increase sympathetic tone, cardiac output, and pain tolerance. Amphetamine at therapeutic doses has been shown to improve time-to-exhaustion on cycle ergometry by 3 to 8%, with corresponding peak watt increases 11. The mechanism involves both central and peripheral stimulation: increased catecholamine release, elevated maximal heart rate, and delayed perception of fatigue.

Caffeine

Caffeine is the most commonly consumed ergogenic substance on the planet. At doses of 3 to 6 mg/kg body weight, taken 30 to 60 minutes before testing, caffeine improves endurance performance by a weighted mean of 3.3% according to a 2021 umbrella review of 21 meta-analyses 12. Peak power output on a Watt test increases by roughly 2 to 4% 13. The ISSN position stand on caffeine and exercise performance confirms: "Caffeine is effective for enhancing various aspects of exercise performance in most but not all studies" 14.

Habitual caffeine users develop partial tolerance, but a 200 mg dose still produces measurable ergogenic effects even in daily consumers.

Bronchodilators

Short-acting beta-2 agonists (albuterol, salbutamol) and long-acting agents (formoterol, salmeterol) reduce airway resistance. In patients with exercise-induced bronchoconstriction, bronchodilators may increase VO2 max by 5 to 10% by restoring normal ventilation 15. In non-asthmatic individuals, the effect is minimal at inhaled doses but becomes significant with oral or high-dose inhaled administration, which is why the World Anti-Doping Agency restricts systemic beta-2 agonist use.

Hormonal and Metabolic Therapies: Nuanced Effects

GLP-1 Receptor Agonists

Semaglutide and tirzepatide reduce body mass substantially. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 16. Because VO2 max is expressed per kilogram, weight loss raises the relative value even if absolute oxygen uptake stays flat or slightly declines due to loss of metabolically active tissue.

A patient who loses 15 kg on semaglutide might see VO2 max jump from 28 to 33 mL/kg/min without any improvement in true cardiac or pulmonary function. Conversely, the SURMOUNT-1 trial (N=2,539) with tirzepatide 15 mg showed 22.5% weight loss 17, enough to shift a patient from "below average" to "average" CRF categories on standard age-sex tables.

The clinical question becomes whether relative or absolute VO2 max better reflects functional capacity in patients on anti-obesity medications. Both numbers should be documented.

Thyroid Hormones

Hyperthyroidism (endogenous or from levothyroxine over-replacement) increases resting metabolic rate, heart rate, and cardiac output. Mild thyrotoxicosis may modestly increase VO2 max, but severe hyperthyroidism paradoxically reduces exercise capacity through skeletal-muscle myopathy and cardiac arrhythmia 18. Hypothyroidism, or under-replacement with levothyroxine, reduces VO2 max by 15 to 25% in some studies 19.

Iron Supplementation

In iron-deficient patients (ferritin <30 ng/mL), intravenous iron repletion improves VO2 max by 3 to 7% through restored hemoglobin synthesis and improved mitochondrial enzyme function 20. This is a correction of pathology, not a distortion. But it means that a patient tested before and after iron repletion will show different results, and the change should not be attributed to fitness gains alone.

How to Get Accurate Results

The American College of Sports Medicine (ACSM) guidelines for exercise testing recommend documenting all current medications, supplements, and recent dosing changes before any CRF assessment 21. Testing facilities should follow a standardized checklist.

Dr. Benjamin Levine, Director of the Institute for Exercise and Environmental Medicine, has stated: "VO2 max is only as reliable as the conditions under which it is measured. Medications, hydration status, sleep, and ambient temperature all affect the result."

Practical pre-test instructions include the following. Disclose all prescription medications, OTC drugs, and supplements at intake. Avoid caffeine for at least 12 hours (some protocols specify 24 hours). Take beta-blockers at the same time and dose for each serial test, or work with your prescriber to hold the dose identically each time (only if clinically safe). Maintain consistent hydration, consuming 500 mL of water in the two hours before testing. If on testosterone therapy, schedule tests at the same point in the injection cycle (typically trough, one day before the next injection). Note any recent illness, altitude exposure, or sleep deprivation that could independently alter results.

For patients on GLP-1 agonists who are actively losing weight, recording both absolute VO2 (L/min) and relative VO2 (mL/kg/min) provides a more complete picture.

When Drug Effects Are Clinically Relevant vs. Testing Artifacts

Not every drug-related shift in VO2 max represents a "distortion." A patient on atenolol 50 mg daily for rate control is living at their beta-blocked VO2 max. That number reflects their real exercise ceiling. The distortion problem arises in two scenarios: comparing tests taken on and off the medication without annotation, or attributing a medication-driven change to fitness improvement or decline.

If a patient switches from metoprolol to lisinopril and repeats CRF testing two months later, the apparent 10% VO2 max gain reflects removal of beta-blockade, not two months of cardiovascular adaptation. Similarly, a patient starting TRT who also begins a structured exercise program cannot separate drug-mediated hematologic gains from training-induced gains without additional markers (reticulocyte count, training load data).

The clinical standard is straightforward: document medication status on every test report and interpret serial changes in context. A 3% VO2 max change in a patient whose medications, body weight, and hydration have remained stable is meaningful. The same change in a patient who just started semaglutide and stopped propranolol tells you almost nothing about fitness.

Serial testing intervals of 8 to 12 weeks, with medication and body-composition data recorded alongside each test, produce the most interpretable longitudinal trends. Shorter intervals risk confounding from adaptation to the test protocol itself.